Nowadays,a number of promising strategies are being developed that aim at combining diagnostic and therapeutic capabilities into clinically effective formulations.Thus,the combination of a modified release provided by...Nowadays,a number of promising strategies are being developed that aim at combining diagnostic and therapeutic capabilities into clinically effective formulations.Thus,the combination of a modified release provided by an organic encapsulation and the intrinsic physico-chemical properties from an inorganic counterpart opens new perspectives in biomedical applications.Herein,a biocompatible magnetic lipid nanocomposite vehicle was developed through an efficient,green and simple method to simultaneously incorporate magnetic nanoparticles and an anticancer drug(doxorubicin)into a natural nano-matrix.The theranostic performance of the final magnetic formulation was validated in vitro and in vivo,in melanoma tumors.The systemic administration of the proposed magnetic hybrid nanocomposite carrier enhanced anti-tumoral activity through a synergistic combination of magnetic hyperthermia effects and antimitotic therapy,together with MRI reporting capability.The application of an alternating magnetic field was found to play a dual role,(i)acting as an extra layer of control(remote,on-demand)over the chemotherapy release and(ii)inducing a local thermal ablation of tumor cells.This combination of chemotherapy with thermotherapy establishes a synergistic platform for the treatment of solid malignant tumors under lower drug dosing schemes,which may realize the dual goal of reduced systemic toxicity and enhanced anti-tumoral efficacy.展开更多
基金partially supported by NORTE 2020(2014-2020 North Portugal Regional Operational Program)the ERDF(European Regional Development Fund)under Grant NORTE-01-0145-FEDER-000019+7 种基金by European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No.686009by“TAMs-targeted and externally controlled nanotheranostics of triple-negative-breast-cancer(Nanother)"project UTAP-EXPL/NTec/0038/2017by“Local specific treatment of triple-negative-breast-cancer through externally triggered target-less drug carriers(MagtargetON)"project NORTE-01-0145-FEDER-031142co-funded by FCT and the ERDF through NORTE2020by 2014-2020 INTERREG Cooperation Programme Spain-Portugal(POCTEP)through the project 0624_2IQBIONEURO_6_Esupport from Raman4clinics COST Action BM1401 and Radiomag COST action TD1402the ERDF and the Spanish MINECO under project ref.PI19/00349(AES 2019)the Instituto de Salud Carlos Ⅲ for the Sara Borrell Grant(CD19/00035).
文摘Nowadays,a number of promising strategies are being developed that aim at combining diagnostic and therapeutic capabilities into clinically effective formulations.Thus,the combination of a modified release provided by an organic encapsulation and the intrinsic physico-chemical properties from an inorganic counterpart opens new perspectives in biomedical applications.Herein,a biocompatible magnetic lipid nanocomposite vehicle was developed through an efficient,green and simple method to simultaneously incorporate magnetic nanoparticles and an anticancer drug(doxorubicin)into a natural nano-matrix.The theranostic performance of the final magnetic formulation was validated in vitro and in vivo,in melanoma tumors.The systemic administration of the proposed magnetic hybrid nanocomposite carrier enhanced anti-tumoral activity through a synergistic combination of magnetic hyperthermia effects and antimitotic therapy,together with MRI reporting capability.The application of an alternating magnetic field was found to play a dual role,(i)acting as an extra layer of control(remote,on-demand)over the chemotherapy release and(ii)inducing a local thermal ablation of tumor cells.This combination of chemotherapy with thermotherapy establishes a synergistic platform for the treatment of solid malignant tumors under lower drug dosing schemes,which may realize the dual goal of reduced systemic toxicity and enhanced anti-tumoral efficacy.